Literature DB >> 6707913

Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.

R L Friedman, R J Barrett, E Sanders-Bush.   

Abstract

The relative abilities of putative serotonin (5-HT) antagonists to block the quipazine discriminative cue were compared with their relative potencies to compete for the 5-HT1 and 5-HT2 binding sites in the brain. Male Sprague-Dawley rats were trained to discriminate 2.5 mg/kg of quipazine from saline. Once training was complete, antagonists were administered 90 min before a 5-min test with 1 mg/kg of quipazine, a dose which gave 75% responding on the quipazine lever. A dose-response curve was generated for each antagonist and an ID50 value (dose that inhibits responding to 50% on the quipazine lever) was determined by log-logit analysis. The binding of [3H]-5-HT to the 5-HT1 site and of [3H]spiperone to the 5-HT2 site was determined in crude membranes prepared from frontal cortex ( [3H]spiperone) or pons-medulla ( [3H]-5-HT) of naive rats. IC50 values for the antagonists were determined by log-logit analyses of competition binding curves. The ID50 values for the blockade of the quipazine discrimination by the 5-HT antagonists correlated significantly with their affinities for the 5-HT2 binding site (r = 0.87). In contrast, no correlation existed between effects on the behavioral measure and affinities for the 5-HT1 site (r = 0.15). These results suggest that the quipazine cue is mediated by an action at central 5-HT2 sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707913

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Discriminative stimulus properties of the serotonin agonist MK 212.

Authors:  K A Cunningham; P M Callahan; J B Appel
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Evidence for 5-HT2 receptor mediation in quipazine anorexia.

Authors:  R Shukla; D MacKenzie-Taylor; R H Rech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.

Authors:  D Fiorella; S Helsley; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

6.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis.

Authors:  D Fiorella; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  Circadian variation in behavioural responses to central 5-HT receptor stimulation in the mouse.

Authors:  P C Moser; P H Redfern
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Mianserin as a discriminative stimulus in rats: asymmetrical cross-generalization with scopolamine.

Authors:  B M Kelley; J H Porter; S A Varvel
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

9.  Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.

Authors:  D Marona-Lewicka; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

10.  Abnormal development of monoaminergic neurons is implicated in mood fluctuations and bipolar disorder.

Authors:  Marin M Jukic; Tania Carrillo-Roa; Michal Bar; Gal Becker; Vukasin M Jovanovic; Ksenija Zega; Elisabeth B Binder; Claude Brodski
Journal:  Neuropsychopharmacology       Date:  2014-09-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.